BENZONATATE BENZONATATE QPHARMA, INC. FDA Approved Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7. Each soft gelatin capsule, for oral administration, contains 100 mg, 150 mg or 200 mg of benzonatate USP. Benzonatate Capsules, USP also contain the following inactive ingredients: D&C Yellow #10, gelatin, glycerin, purified water, methylparaben and propylparaben. structure
Generic: BENZONATATE
Mfr: QPHARMA, INC. FDA Rx Only
FunFoxMeds bottle
Substance Benzonatate
Route
ORAL
Applications
ANDA040627
Package NDC

Drug Facts

Composition & Profile

Strengths
200 mg
Quantities
603 count
Treats Conditions
Indications Usage Benzonatate Usp Is Indicated For The Symptomatic Relief Of Cough
Pill Appearance
Shape: capsule Color: yellow Imprint: 106

Identifiers & Packaging

Container Type BOTTLE
All Product Codes
UNII
5P4DHS6ENR
Packaging

HOW SUPPLIED Benzonatate Capsules USP, 200 mg: Yellow soft gelatin capsules, imprinted “106”, available in bottles of 21 (NDC 42708-082-21) Store at 20°C to 25° C (68°F to 77°F). [See USP Controlled Room Temperature]. PROTECT FROM LIGHT . Manufactured by: Softgel Healthcare Pvt. Ltd., Survey No. 20/1, Vandalur-Kelambakkam Road, Pudupakkam, Chengalpattu, Tamilnadu - 603 103, India. Distributed by: Ascend Laboratories, LLC Bedminster, NJ 07921 Revised: November 2025 PT3732-01 (2411326); Principal Display Panel NDC: 42708-082-21 Label

Package Descriptions
  • HOW SUPPLIED Benzonatate Capsules USP, 200 mg: Yellow soft gelatin capsules, imprinted “106”, available in bottles of 21 (NDC 42708-082-21) Store at 20°C to 25° C (68°F to 77°F). [See USP Controlled Room Temperature]. PROTECT FROM LIGHT . Manufactured by: Softgel Healthcare Pvt. Ltd., Survey No. 20/1, Vandalur-Kelambakkam Road, Pudupakkam, Chengalpattu, Tamilnadu - 603 103, India. Distributed by: Ascend Laboratories, LLC Bedminster, NJ 07921 Revised: November 2025 PT3732-01 (2411326)
  • Principal Display Panel NDC: 42708-082-21 Label

Overview

Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7. Each soft gelatin capsule, for oral administration, contains 100 mg, 150 mg or 200 mg of benzonatate USP. Benzonatate Capsules, USP also contain the following inactive ingredients: D&C Yellow #10, gelatin, glycerin, purified water, methylparaben and propylparaben. structure

Indications & Usage

INDICATIONS & USAGE Benzonatate USP is indicated for the symptomatic relief of cough.

Dosage & Administration

DOSAGE & ADMINISTRATION Adults and Children over 10 years of age: Usual dose is one 100 mg, 150 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate should be swallowed whole . Benzonatate capsules are not to be broken, chewed, dissolved, cut or crushed.

Warnings & Precautions
WARNINGS Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. Psychiatric Effects Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs. Accidental Ingestion and Death in Children Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE ).
Contraindications

Hypersensitivity to benzonatate or related compounds.

Adverse Reactions

Potential Adverse Reactions to benzonatate may include: Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule. CNS : sedation; headache; dizziness; mental confusion; visual hallucinations. GI : constipation; nausea; GI upset. Dermatologic : pruritus; skin eruptions. Other : nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children.


Similar Drugs

Related medications based on brand, generic name, substance, active ingredients.

View all similar drugs →